We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11B
AUM Growth
+$1.48B
Cap. Flow
-$1.03B
Cap. Flow %
-9.36%
Top 10 Hldgs %
83.4%
Holding
140
New
7
Increased
14
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.6M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$44.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.8M
4
NGNE icon
Neurogene
NGNE
+$28.1M
5
EXEL icon
Exelixis
EXEL
+$25.4M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$24.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
3
NVAX icon
Novavax
NVAX
+$17.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
5
INSM icon
Insmed
INSM
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.76%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
51
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.28M 0.08%
609,166
– –
IMGN
52
DELISTED
Immunogen Inc
IMGN
$8.08M 0.07%
3,015,353
– –
LGND icon
53
Ligand Pharmaceuticals
LGND
$5.86B
$7.49M 0.07%
117,638
– –
ALDR
54
DELISTED
Alder Biopharmaceuticals
ALDR
$7.12M 0.06%
217,328
– –
RARE icon
55
Ultragenyx Pharmaceutical
RARE
$2.48B
$7.09M 0.06%
100,000
-10,894
-10% -$695K
TRIL
56
DELISTED
Trillium Therapeutics Inc.
TRIL
$6.12M 0.06%
413,697
+201,905
+95% +$2.32M
INSM icon
57
Insmed
INSM
$22.7B
$5.81M 0.05%
400,000
-1,100,000
-73% -$13.8M
ARCT icon
58
Arcturus Therapeutics
ARCT
$166M
$5.77M 0.05%
333,766
– –
PRQR icon
59
ProQR Therapeutics
PRQR
$253M
$5.74M 0.05%
860,464
-373,631
-30% -$2.06M
NDRM
60
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$5.64M 0.05%
305,000
– –
CPRX
61
DELISTED
Catalyst Pharmaceutical
CPRX
$5.56M 0.05%
5,102,153
-20,000
-0.4% -$18K
NTRA icon
62
Natera
NTRA
$36.8B
$5M 0.05%
450,000
– –
GNMX
63
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.91M 0.04%
880,539
– –
AKTX
64
Akari Therapeutics
AKTX
$14.4M
$4.23M 0.04%
621
– –
NERV icon
65
Minerva Neurosciences
NERV
$196M
$3.65M 0.03%
32,351
-31,200
-49% -$3.03M
STML
66
DELISTED
Stemline Therapeutics, Inc.
STML
$3.61M 0.03%
333,497
– –
LOXO
67
DELISTED
Loxo Oncology, Inc
LOXO
$3.61M 0.03%
137,735
– –
RXDX
68
DELISTED
Ignyta, Inc.
RXDX
$3.59M 0.03%
571,000
– –
VIRX
69
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.24M 0.03%
21,190
– –
CNCE
70
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$3.21M 0.03%
316,976
-153,082
-33% -$1.67M
TRVN
71
DELISTED
Trevena, Inc.
TRVN
$3.04M 0.03%
720
– –
SYRS
72
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.84M 0.03%
20,447
– –
ADMS
73
DELISTED
Adamas Pharmaceuticals
ADMS
$2.83M 0.03%
172,630
– –
TARA icon
74
Protara Therapeutics
TARA
$218M
$2.79M 0.03%
7,465
– –
CBIO
75
Crescent Biopharma
CBIO
$557M
$2.73M 0.02%
3,812
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Baker Bros. Advisors held 140 positions worth $11B, up 16% from $9.54B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.03B in Q3 2016, closing 6 positions and reducing 16 holdings. Its most notable exit was XENOPORT, INC., an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 81% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in ContraFect Corporation worth $10M.

  • Baker Bros. Advisors's largest Q3 2016 buy was ContraFect Corporation: 5,057 shares worth $10M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2016, an estimated $55.6M increase.
  • Baker Bros. Advisors's biggest Q3 2016 reduction was BioCryst Pharmaceuticals, cutting an estimated $16.2M.
  • Baker Bros. Advisors fully exited XENOPORT, INC. in Q3 2016, selling an estimated $24.5M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $11B portfolio in Q3 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 6 in Q3 2016.
  • Baker Bros. Advisors's portfolio value rose 16% quarter-over-quarter to $11B.

Based on Baker Bros. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.